GLP-1 and Multi-Receptor Research Materials: A Comparison Map
Direct answer: Semaglutide, tirzepatide and retatrutide belong to different receptor profiles: GLP-1; GIP plus GLP-1; and glucagon plus GIP plus GLP-1, respectively. Cagrilintide belongs to amylin/calcitonin receptor pharmacology. A useful comparison identifies the receptor combination first, then asks what the experiment measured. Counting targets alone cannot rank the compounds.
Start with the receptor names, not a leaderboard
A receptor agonist is a molecule that activates a receptor in a defined biological system. The term describes an interaction, not a complete account of the molecule's behavior. A multi-receptor agonist has activity at more than one receptor; the relative activity can differ across those receptors and across experimental conditions.
This distinction makes the GLP-1 Peptides collection easier to navigate. Its neighboring compounds may be relevant to the same broad research question without having identical targets. A category is useful for finding related materials, while a receptor map explains why they should occupy separate rows in a comparison.
The following map summarizes published target classifications. It deliberately omits numerical potency rankings, because those require matched assays and reference standards.
| Material | Published receptor framing | Useful first comparison | Evidence to avoid substituting |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Other GLP-1R measurements using the same endpoint | An unrelated receptor assay |
| Tirzepatide | GIPR and GLP-1R agonist | Separate measurements at each incretin receptor | A single combined potency score |
| Retatrutide | GCGR, GIPR and GLP-1R agonist | A three-receptor profile | An assumption of equal activity at all three targets |
| Mazdutide | GLP-1R and GCGR dual agonist | Other GLP-1/glucagon profiles | Tirzepatide data merely because both are called dual agonists |
| Survodutide | GCGR and GLP-1R dual agonist | Its own discovery and receptor-assay data | Mazdutide results treated as interchangeable |
| Cagrilintide | Amylin/calcitonin receptor agonist | Calcitonin-family receptor experiments | GLP-1R pharmacology assigned by association |
Three core compounds, three different starting points
The semaglutide discovery study describes a GLP-1 analogue whose design considered receptor activity, metabolic stability and albumin affinity. Those are distinct properties: a change that affects association with albumin is not automatically a change in receptor selectivity. Semaglutide is therefore the single-receptor reference point in this map, rather than a generic name for everything in the category.
The tirzepatide discovery paper studied LY3298176 through receptor-expressing cells, functional assays and additional experimental systems. It establishes the GIP/GLP-1 framing for Tirzepatide. When reading that paper, separate the evidence that each receptor is engaged from evidence about a downstream response. A receptor profile and a model-level endpoint answer different questions.
Retatrutide, identified as LY3437943 in its discovery study, adds glucagon-receptor activity to the GIP/GLP-1 profile. The reported in-vitro activities were not equal across the three targets. This is a concrete reason to avoid treating “triple” as a multiplier: it describes breadth of target engagement, not three times a measured effect.
Why two dual agonists may belong in different columns
Tirzepatide combines GIPR and GLP-1R activity. Mazdutide and survodutide are described in GLP-1R/GCGR research. The shared word “dual” conceals the most important distinction if the target names are removed.
The mazdutide trial report identifies its GLP-1/glucagon classification. The survodutide discovery study provides a separate preclinical characterization of BI 456906. These sources support separate identities, not a pooled conclusion about every dual agonist. This article uses them for classification; it does not convert their outcomes into claims for catalog materials.
A comparison worksheet should therefore spell out both receptor names rather than abbreviating every row to “dual.” That small change prevents an apparent similarity in vocabulary from becoming a false equivalence in the analysis.
Cagrilintide sits beside the incretin map
The AM833 pharmacology study places cagrilintide in the calcitonin-family receptor system. Its inclusion in metabolic research does not make it a GLP-1 agonist. The distinction is especially useful when reading about combinations: two ingredients can address different receptor families without becoming one new receptor-selective molecule.
Our cagrilintide and amylin explainer follows that branch of the map in more detail. Keeping it separate allows an article about incretin receptors to remain focused while giving readers a relevant path into adjacent biology.
Move from the map to a fair comparison
Once the targets are clear, choose a question narrow enough for the data. Binding, cAMP accumulation and receptor internalization are different measurements. The receptor-assay comparison explains how to read those differences. Before comparing two numbers, check the receptor species, cell system, reference ligand and normalization method.
Also keep material identity separate from the published result. A source about a named molecule cannot verify a different supplied batch. When following a material from the NEXTWAVE PEPTIDES catalog to its documentation, use the matching COA; the peptide COA guide explains which analytical questions a report can answer.
Limits of this receptor map
This is a selective classification guide, not a systematic review or a head-to-head experiment. The cited studies differ in design and include distinct cell, animal and clinical settings. Their classification evidence is useful here, but their numerical outcomes should not be merged into a cross-compound ranking. No published study cited on this page establishes the analytical properties or biological activity of a NEXTWAVE PEPTIDES lot.
FAQ
Does a triple agonist act equally at three receptors?
No. Three-receptor activity identifies a target set. Relative activity must be measured separately at each receptor under stated conditions.
Are tirzepatide and mazdutide the same type of dual agonist?
They share the count of two targets, but not the same pair: tirzepatide is framed around GIPR/GLP-1R, whereas mazdutide is framed around GLP-1R/GCGR.
Why include cagrilintide in this overview?
It helps explain the boundary of the map. Cagrilintide appears in adjacent metabolic research, yet its amylin/calcitonin pharmacology should remain a separate branch.
Can this table identify the best compound?
No. It helps select relevant sources and comparison groups. A ranking would require a specified endpoint and evidence collected under sufficiently comparable conditions.